دورية أكاديمية
Recombinant proteins production in Escherichia coli BL21 for vaccine applications: a cost estimation of potential industrial-scale production scenarios.
| العنوان: | Recombinant proteins production in Escherichia coli BL21 for vaccine applications: a cost estimation of potential industrial-scale production scenarios. |
|---|---|
| المؤلفون: | Akmayan I; Department of Molecular Biology and Genetics, Yildiz Technical University, Istanbul, Türkiye., Ozturk AB; Department of Chemical Engineering, Yildiz Technical University, Istanbul, Türkiye., Ozbek T; Department of Molecular Biology and Genetics, Yildiz Technical University, Istanbul, Türkiye. |
| المصدر: | Preparative biochemistry & biotechnology [Prep Biochem Biotechnol] 2024 Jan 10, pp. 1-14. Date of Electronic Publication: 2024 Jan 10. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 9607037 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-2297 (Electronic) Linking ISSN: 10826068 NLM ISO Abbreviation: Prep Biochem Biotechnol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2005-> : Abingdon, Oxford : Taylor & Francis Original Publication: New York, NY : Marcel Dekker, c1996- |
| مستخلص: | Recent SARS-CoV-2 pandemic elevated research interest in microorganism-related diseases, and protective health application importance such as vaccination and immune promoter agents emerged. Among the production methods for proteins, recombinant technology is an efficient alternative and frequently preferred method. However, since the production and purification processes vary due to the protein nature, the effect of these differences on the cost remains ambiguous. In this study, brucellosis and its two important vaccine candidate proteins (rOmp25 and rEipB) with different properties were selected as models, and industrial-scale production processes were compared with the SuperPro Designer ® for estimating the unit production cost. Simulation study showed raw material cost by roughly 60% was one of the barriers to lower-cost production and 52.5 and 559.8 $/g were estimated for rEipB and rOmp25, respectively. |
| فهرسة مساهمة: | Keywords: Cost estimation; Process simulation; Prokaryotic expression system; Recombinant protein; Vaccine Local Abstract: [plain-language-summary] HighlightsTechno-economic evaluation of recombinant protein produced for vaccine purposesRecombinant proteins rOmp25 and rEipB production process using E.coli BL21Effect of outer membrane and periplasmic space proteins on purification costSimulated cost estimation of rEipB and rOmp25 were 52.5 and 559.8 $/g, respectively. |
| تواريخ الأحداث: | Date Created: 20240110 Latest Revision: 20240110 |
| رمز التحديث: | 20240111 |
| DOI: | 10.1080/10826068.2023.2299495 |
| PMID: | 38198230 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher 
Full Text Finder | تدمد: | 1532-2297 |
|---|---|
| DOI: | 10.1080/10826068.2023.2299495 |